Randomized Phase 2/3 Study of αβ T-Cell-Depleted, Related Haploidentical Hematopoietic Stem Cell Transplant Plus BPX 501 T-Cell Infusion vs Haplo-HSCT Plus Post Transplant Cyclophosphamide in Patients With AML or MDS
Phase of Trial: Phase II/III
Latest Information Update: 10 Jan 2019
At a glance
- Drugs Rivogenlecleucel (Primary) ; Cyclophosphamide; Rimiducid
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms THRIVE
- Sponsors Bellicum Pharmaceuticals
- 04 Jan 2019 Status changed from not yet recruiting to recruiting.
- 05 Nov 2018 Planned End Date changed from 1 May 2024 to 1 Jun 2024.
- 05 Nov 2018 Planned primary completion date changed from 1 Nov 2023 to 1 Dec 2023.